Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

BACKGROUND We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth in patients with severe isolated PLD. We have now completed an open-label extension for one additional year to assess safety and clinical benefits of continued use of OctLAR for 2 years (O → O) and examined drug effect in the placebo group who crossed over to OctLAR in Year 2 (P → O). METHODS The primary end point was change in total liver volume (TLV) measured by magnetic resonance imaging (MRI); secondary end points were changes in total kidney volume (TKV) measured by MRI, glomerular filtration rate (GFR), quality of life (QOL), safety, vital signs and laboratory parameters. RESULTS Forty-one of 42 patients received OctLAR (n = 28) or placebo (n = 14) in Year 1 and received OctLAR in Year 2 (maximum dose 40 mg). Patients originally randomized to placebo (P → O) showed substantial reduction in TLV after treatment with OctLAR in Year 2 (Δ% -7.66 ± 9.69%, P = 0.011). The initial reduction of TLV in the OctLAR group (O → O) was maintained for 2 years (Δ% -5.96 ± 8.90%), although did not change significantly during Year 2 (Δ% -0.77 ± 6.82%). OctLAR inhibited renal enlargement during Year 1 (Δ% +0.42 ± 7.61%) in the (O → O) group and during Year 2 (Δ% -0.41 ± 9.45%) in the (P → O) group, but not throughout Year 2 (Δ% +6.49 ± 7.08%) in the (O → O) group. Using pooled analyses of all individuals who received OctLAR for 12 months, i.e. in Year 1 for O → O patients and Year 2 for P → O patients, average reduction in TLV was -6.08 ± 7.58% (P = 0.001) compared to net growth of 0.9 ± 8.35% in the original placebo group. OctLAR-treated individuals continued to experience improvements in QOL in Year 2, although overall physical and mental improvements were not significant during Year 2 compared to Year 1. Changes in GFR were similar in both groups. CONCLUSION Over 2 years, OctLAR significantly reduced the rate of increase in TLV and possibly the rate of increase in TKV.

[1]  Douglas Landsittel,et al.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[2]  M. Burke,et al.  CARCINOID TUMOUR MANAGEMENT IN HAEMODIALYSIS: A CASE REPORT , 2012, Nephrology.

[3]  J. Drenth,et al.  Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial , 2011, Trials.

[4]  R. Peces,et al.  Octreotide reduces hepatic, renal and breast cystic volume in autosomal-dominant polycystic kidney disease , 2011, International Urology and Nephrology.

[5]  K. Jhaveri,et al.  Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  James Glockner,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[7]  L. Antiga,et al.  Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[8]  L. van Keimpema,et al.  Effect of octreotide on polycystic liver volume , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[9]  M. V. van Oijen,et al.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.

[10]  Richard A. Robb,et al.  New software toolkits for comprehensive visualization and analysis of three-dimensional multimodal biomedical images , 1997, Journal of Digital Imaging.

[11]  L. van Keimpema,et al.  Somatostatin analogues reduce liver volume in polycystic liver disease , 2008, Gut.

[12]  N. LaRusso,et al.  Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. , 2007, Gastroenterology.

[13]  P. Lai,et al.  Octreotide therapy for chylous ascites in a chronic dialysis patient , 2005, Nephrology.

[14]  L. Antiga,et al.  Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. , 2005, Kidney international.

[15]  M. Wolzt,et al.  Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release. , 2002, Kidney international.

[16]  C. Falk,et al.  Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. , 2000, American journal of human genetics.

[17]  M J Puddephat,et al.  The benefit of stereology for quantitative radiology. , 2000, The British journal of radiology.

[18]  B. Bloch,et al.  In vivo regulation of intraneuronal trafficking of G protein-coupled receptors for neurotransmitters. , 1999, Trends in pharmacological sciences.

[19]  I. Lancranjan,et al.  Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly , 1998, Clinical endocrinology.

[20]  H. Betz,et al.  Somatostatin Inhibits Excitatory Transmission at Rat Hippocampal Synapses via Presynaptic Receptors , 1997, The Journal of Neuroscience.

[21]  J. Edwardson,et al.  Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization , 1997, British journal of pharmacology.

[22]  M. Veysey,et al.  Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. , 1996, Gut.

[23]  R. G. Walker,et al.  Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 , 1994, The Lancet.

[24]  C. Sullivan,et al.  Effects of long term octreotide on gall stone formation and gall bladder function. , 1992, BMJ.

[25]  L. Lazarus,et al.  Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. , 1990, Annals of internal medicine.